ZA9505642B - Lyophilized imaging agent formulation - Google Patents

Lyophilized imaging agent formulation

Info

Publication number
ZA9505642B
ZA9505642B ZA9505642A ZA9505642A ZA9505642B ZA 9505642 B ZA9505642 B ZA 9505642B ZA 9505642 A ZA9505642 A ZA 9505642A ZA 9505642 A ZA9505642 A ZA 9505642A ZA 9505642 B ZA9505642 B ZA 9505642B
Authority
ZA
South Africa
Prior art keywords
imaging agent
agent formulation
lyophilized imaging
lyophilized
formulation
Prior art date
Application number
ZA9505642A
Inventor
Diane C Corbo
Mary Jean M Link
Scott K Larsen
Howard F Solomon
Michelle L Tomsho
Robert L Suddith
Michael Bornstein
N Adeyinka Williams
Original Assignee
Ortho Pharma Corp
Johnson Matthey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US27181894A priority Critical
Application filed by Ortho Pharma Corp, Johnson Matthey Inc filed Critical Ortho Pharma Corp
Publication of ZA9505642B publication Critical patent/ZA9505642B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
ZA9505642A 1994-07-07 1995-07-06 Lyophilized imaging agent formulation ZA9505642B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US27181894A true 1994-07-07 1994-07-07

Publications (1)

Publication Number Publication Date
ZA9505642B true ZA9505642B (en) 1997-05-06

Family

ID=23037222

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9505642A ZA9505642B (en) 1994-07-07 1995-07-06 Lyophilized imaging agent formulation

Country Status (2)

Country Link
US (1) US6024938A (en)
ZA (1) ZA9505642B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040022857A1 (en) * 2002-07-31 2004-02-05 Uzgiris Egidijus E. Synthesis of highly conjugated polymers
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
JP2006522100A (en) * 2003-03-10 2006-09-28 バイオジェン アイデック インク Thiol-mediated drug binding to targeting peptides
AU2003901515A0 (en) * 2003-04-02 2003-04-17 Norika Holdings Sterilisation process for pharmaceutical product
US20040225214A1 (en) * 2003-05-07 2004-11-11 General Electric Company Method of high-throughput quantitative pet for small animal imaging using a large-bore pet scanner for the assessment of pet tracer performance
US6987270B2 (en) * 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
US20070189965A1 (en) * 2004-06-17 2007-08-16 Kuperus John H Copper-complex isonitrile positron emission tomography (pet) imaging agent and method
US7229603B2 (en) * 2004-06-17 2007-06-12 Anazaohealth Corporation Stablilized and lyophilized radiopharmaceutical agents
US8115373B2 (en) 2005-07-06 2012-02-14 Rochester Institute Of Technology Self-regenerating particulate trap systems for emissions and methods thereof
ES2712942T3 (en) 2006-03-10 2019-05-16 Wyeth Llc Anti-5T4 antibodies and uses thereof
KR20140071452A (en) 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 Antibody purification
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20070259434A1 (en) * 2006-05-05 2007-11-08 Atomic Energy Council-Institute Of Nuclear Energy Research Rapid method for determining radiochemical purity of in-111-pentetreotide
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd Methods for treating juvenile idiopathic arthritis
WO2010042815A2 (en) * 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
JP2012510468A (en) * 2008-11-28 2012-05-10 アボット・ラボラトリーズAbbott Laboratories Stable antibody composition and method for stabilizing the same
CA2760185A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha antibodies
MX351220B (en) 2010-11-05 2017-10-05 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity.
AU2011325974B2 (en) 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
CN103499648B (en) * 2013-09-18 2014-06-11 青岛首和金海制药有限公司 Mannitol nicotinate quality control method
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
CN105828841A (en) 2013-11-04 2016-08-03 辉瑞大药厂 Anti-Efna4 Antibody-Drug Conjugates
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2947148A1 (en) 2014-04-30 2015-11-05 Pfizer Inc. Anti-ptk7 antibody-drug conjugates
US20190048073A1 (en) 2017-07-20 2019-02-14 Pfizer Inc. Anti-gd3 antibodies and antibody-drug conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
EP0417193B1 (en) * 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US5759515A (en) * 1989-08-09 1998-06-02 Rhomed Incorporated Polyvalent peptide pharmaceutical applications
CA1340250C (en) * 1989-09-18 1998-12-15 Hans J. Hansen Method for rapidly radiolabeling monovalent antibody fragments with technetium
US5700444A (en) * 1992-02-20 1997-12-23 Rhomed Incorporated Chemotactic peptide pharmaceutical applications
JPH07504902A (en) * 1992-03-13 1995-06-01
GB9209641D0 (en) * 1992-05-02 1992-06-17 Johnson Matthey Plc Improvements in radiolabelling

Also Published As

Publication number Publication date
US6024938A (en) 2000-02-15

Similar Documents

Publication Publication Date Title
GB2337461B (en) Formulation
GB2309145B (en) Image construction
GB2298789B (en) Pharmaceutical compositions
EG24118A (en) Pharmaceutical compositions
DE69905368D1 (en) Oxydiertes thymosin beta 4
GB2288732B (en) Pharmaceutical compositions
HK1011278A1 (en) Macrolide formulations
NZ248812A (en) Mr imaging composition
GB9412273D0 (en) Administration means
GB9519363D0 (en) Pharmaceutical formulation
AU2187995A (en) X-ray imaging system
ZA9701788B (en) Skin toning formulation
GB9608719D0 (en) Pharmaceutical compositions
ZA9704486B (en) Concentrated antibody formulation
GB9725094D0 (en) Imaging systems
ZA9402035B (en) Protein formulation
IL113901D0 (en) 1-phenyl-3-dimethylaminopropane compounds their preparation and use
GB2326093B (en) Avermectin formulation
IL125428D0 (en) Uv-protection formulation
AU7702994A (en) Contrast agent
GB9420657D0 (en) Contrast agents
GB9417524D0 (en) Pharmaceutical compositions
HU9203086D0 (en) Contrast agent
CY2211B1 (en) Pharmaceutical compositions
ZA9510687B (en) Sustained release caffeine formulation